Literature DB >> 20856734

Commentary: practice patterns and potential impact on quality measures for a practicing physician.

Cathy Eng, Scott Kopetz.   

Abstract

Year:  2009        PMID： 20856734      PMCID： PMC2790660          DOI： 10.1200/JOP.091013

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

1.  Longitudinal patterns of chemotherapy use in metastatic colorectal cancer.

Authors:  S Yousuf Zafar; Jennifer E Marcello; Jane L Wheeler; Krista L Rowe; Michael A Morse; James E Herndon; Amy P Abernethy
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

Authors:  Giuseppe Colucci; Vittorio Gebbia; Giancarlo Paoletti; Francesco Giuliani; Michele Caruso; Nicola Gebbia; Giacomo Cartenì; Biagio Agostara; Giuseppe Pezzella; Luigi Manzione; Nicola Borsellino; Andrea Misino; Sante Romito; Ernesto Durini; Stefano Cordio; Marisa Di Seri; Massimo Lopez; Evaristo Maiello; Severino Montemurro; Antonio Cramarossa; Vito Lorusso; Maurizio Di Bisceglie; Maurizio Chiarenza; Maria Rosaria Valerio; Teresa Guida; Vita Leonardi; Salvatore Pisconti; Gerardo Rosati; Francesco Carrozza; Giuseppe Nettis; Matteo Valdesi; Gianfranco Filippelli; Santo Fortunato; Sergio Mancarella; Cosimo Brunetti
Journal:  J Clin Oncol       Date:  2005-06-06       Impact factor: 44.544

4.  Variation in the cost of medications for the treatment of colorectal cancer.

Authors:  Salvatore A Ferro; Brian S Myer; Debra A Wolff; Marek S Poniewierski; Eva Culakova; Leon E Cosler; Sarah L Scarpace; Alok A Khorana; Gary H Lyman
Journal:  Am J Manag Care       Date:  2008-11       Impact factor: 2.229

5.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

6.  A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Authors:  Richard M Goldberg; Daniel J Sargent; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Steven R Alberts
Journal:  J Clin Oncol       Date:  2003-12-09       Impact factor: 44.544

7.  Chemotherapy in elderly patients with colorectal cancer.

Authors:  Claus-Henning Köhne; Gunnar Folprecht; Richard M Goldberg; Emmanuel Mitry; Philippe Rougier
Journal:  Oncologist       Date:  2008-04
  7 in total
  1 in total

1.  Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study.

Authors:  Mark A Lewis; Fengmin Zhao; Desiree Jones; Charles L Loprinzi; Joanna Brell; Matthias Weiss; Michael J Fisch
Journal:  J Pain Symptom Manage       Date:  2015-01-14       Impact factor: 3.612
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.